

## CORRIGENDUM

# FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF- $\kappa$ B/Slug-mediated PUMA reduction

D-W Wu, M-C Lee, N-Y Hsu, T-C Wu, J-Y Wu, Y-C Wang, Y-W Cheng, C-Y Chen and H Lee

*Oncogene* (2017) 36, 5439; doi:10.1038/onc.2017.249; published online 17 July 2017

**Correction to:** *Oncogene* (2015) 34, 2505 – 2515; doi:10.1038/onc.2014.184; published online 7 July 2014

Since the publication of the above article, the authors have noticed that the PUMA immunostainings in the 'A549 (NC) treated with cisplatin' panels in Figure 4c was incorrect. The authors acknowledged this was the result of administrative error and have

provided the correct images for the affected panels. A corrected version of Figure 4c is below. The results and conclusions put forth in this article remain unchanged.

The authors would like to apologise for this error and the inconvenience this may have caused.




Figure 4.